PFS
Figure 2 · Panel A
Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Kailun Fei, Jie Zhao, Jiachen Xu, Jianchun Duan, Chengcheng Li, Wenchuan Xie, Jia Zhong, Guoqiang Wang, Yu Xu, Boyang Sun, Rui Wan, Hua Bai, Qinxiang Guo, Wei Guo, Shangli Cai, Zhijie Wang, Jie Wang
Adv Sci (Weinh) 12(48) e06565
Predictive biomarkers are urgently needed for first-line immune checkpoint inhibitors plus chemotherapy (ICI-chemo) in advanced non-small cell lung cancer (NSCLC). Circulating tumor DNA (ctDNA) reflects tumor burden and immunogenicity, potentially identifyinging of patients suitable for ICI-chemo. In this study, pre- and on - treatment tissue and plasma samples are prospectively collected and analyzed from the randomized phase III CHOICE-01 trial comparing ICI - chemo versus chemotherapy alone in advanced NSCLC. Pre-treatment tissue and plasma samples, as well as on-treatment plasma samples, are prospectively collected. Tumor-informed ctDNA detection is based on tissue-identified mutations. Among patients with tumor-informed ctDNA positivity, those receiving ICI-chemo experienced significantly improved-free survival (PFS) and overall survival (OS) compared to those receiving chemotherapy alone (PFS: HR 0.45, 95% CI 0.34-0.60; OS: HR 0.66, 95% CI 0.49-0.88; p = 0.0045). In contrast, no significant differences in PFS or OS are observed between treatment arms in the ctDNA-negative subgroup. The predictive value of tumor-informed ctDNA is independent of other immune biomarkers and superior to other ctDNA metrics. Validation in a combined cohort from RATIONALE 304/307 trials shows similar results. Furthermore, ctDNA clearance during treatment correlates with better clinical outcomes (log-rank p = 0.0004 for OS and p = 0.044 for PFS).
3 个 Figure · 10 个 KM 面板
Figure 2 Predictive role of tumor‐informed ctDNA in the CHOICE‐01 cohort. A,B). Kaplan‐Meier curves comparing progression‐free survival (PFS) between ICI‐chemo and chemotherapy in patients with ctDNA‐negative or ctDNA‐positive status. Upper, Kaplan‐Meier curves depicting the treatment comparison; lower, forest plot depicting the relative efficacy of ICI‐chemo versus chemotherapy. C,D). Kaplan‐Meier curves comparing overall survival (OS), ICI‐chemo, and chemotherapy in patients with tumor‐informed ctDNA‐ or tumor‐informed ctDNA+. Upper, Kaplan‐Meier curves depicting the treatment comparison; lower, forest plot depicting the relative efficacy of chemo‐ICI versus chemotherapy alone. The hazard ratios, corresponding 95% confidence intervals, and statistical significance of the difference were computed using the Cox proportional hazards model.
Figure 2 · Panel A
Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel B
Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel C
Panel C 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel D
Panel D 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 5 Dynamic change of tumor‐informed ctDNA status predicts PFS and OS as a complementary method to imaging. A. Schema of analysis. B‐C. Kaplan–Meier curves comparing overall survival (OS) and progression‐free survival (PFS) between different ctDNA dynamic change groups among patients who were treated with ICI‐chemo in the tumor‐informed ctDNA positive group. The HRs, corresponding 95% CIs, and statistical significance of the difference between the groups were computed using the Cox proportional hazards model. D‐E. Kaplan–Meier curves comparing overall survival (OS) and progression‐free survival (PFS) in patients who were treated with ICI‐chemo stratified by radiographic response in on‐treatment ctDNA‐negative (baseline negative or turned negative at C3D1) and on‐treatment ctDNA‐positive (baseline positive or turned positive at C3D1) populations. P values were calculated by the log‐rank test.
Figure 5 · Panel B
Panel B 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 5 · Panel C
Panel C 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 5 · Panel D
Panel D 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 5 · Panel E
Panel E 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 6 Predictive role of tumor‐informed ctDNA in the RATIONALE‐304/307 cohort. A‐B. Kaplan–Meier curves comparing progression‐free survival (PFS) among patients who were treated with ICI‐chemo versus chemotherapy in patients with tumor‐informed ctDNA+ or tumor‐informed ctDNA‐. Upper, Kaplan–Meier curves depicting the treatment comparison; lower, forest plot depicting the relative efficacy of chemo‐ICI versus chemotherapy. The HRs, corresponding 95% CIs, and statistical significance of the difference between the groups were computed using the Cox proportional hazards model. C. Forest plot depicting the comparison of ICI‐chemo and chemotherapy in tumor‐informed ctDNA+ and tumor‐informed ctDNA‐ groups, non‐lung squamous cell carcinoma (non‐LUSC) and lung squamous cell carcinoma (LUSC), respectively. The HRs, corresponding 95% CIs, and statistical significance of the difference between the groups were computed using the Cox proportional hazards model.
这些图片未产生 KM 曲线结果,不在主页面重复展示。